Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022

OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 antibodies in the Valencian Community (Spain) in October 2022, when BA.5 was the predominant variant. METHOD: Cross-sectional, region-wide, population-based serosurvey study in 88 randomly selected primary care centers of the Valencian Communit...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Sempere, Aníbal, Giménez, Estela, Vanaclocha, Hermelinda, Limón, Ramón, Peiró, Salvador, Navarro, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SESPAS. Published by Elsevier España, S.L.U. 2023
Materias:
Brief Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192597/
https://www.ncbi.nlm.nih.gov/pubmed/37331154
http://dx.doi.org/10.1016/j.gaceta.2023.102312
_version_ 1785043657273901056
author García-Sempere, Aníbal
Giménez, Estela
Vanaclocha, Hermelinda
Limón, Ramón
Peiró, Salvador
Navarro, David
author_facet García-Sempere, Aníbal
Giménez, Estela
Vanaclocha, Hermelinda
Limón, Ramón
Peiró, Salvador
Navarro, David
author_sort García-Sempere, Aníbal
collection PubMed
description OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 antibodies in the Valencian Community (Spain) in October 2022, when BA.5 was the predominant variant. METHOD: Cross-sectional, region-wide, population-based serosurvey study in 88 randomly selected primary care centers of the Valencian Community. RESULTS: Seroprevalence of anti-nucleocapsid (indicative of past infection) and total receptor binding domain (indicative of past infection or vaccination) antibodies was 71.0% (confidence interval [CI]: 67.8-74.2) and 98.4% (CI: 97.5-99.3), respectively. 66.7% (CI: 63.4-70.0) of the population shows hybrid immunity, but only 43.2% in those 80 and over. CONCLUSIONS: The high proportion of hybrid immunity detected is relevant for public health strategies. A second vaccination booster was advisable in the elderly population.
format Online
Article
Text
id pubmed-10192597
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SESPAS. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-101925972023-05-18 Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022 García-Sempere, Aníbal Giménez, Estela Vanaclocha, Hermelinda Limón, Ramón Peiró, Salvador Navarro, David Gac Sanit Brief Original Article OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 antibodies in the Valencian Community (Spain) in October 2022, when BA.5 was the predominant variant. METHOD: Cross-sectional, region-wide, population-based serosurvey study in 88 randomly selected primary care centers of the Valencian Community. RESULTS: Seroprevalence of anti-nucleocapsid (indicative of past infection) and total receptor binding domain (indicative of past infection or vaccination) antibodies was 71.0% (confidence interval [CI]: 67.8-74.2) and 98.4% (CI: 97.5-99.3), respectively. 66.7% (CI: 63.4-70.0) of the population shows hybrid immunity, but only 43.2% in those 80 and over. CONCLUSIONS: The high proportion of hybrid immunity detected is relevant for public health strategies. A second vaccination booster was advisable in the elderly population. SESPAS. Published by Elsevier España, S.L.U. 2023 2023-05-18 /pmc/articles/PMC10192597/ /pubmed/37331154 http://dx.doi.org/10.1016/j.gaceta.2023.102312 Text en © 2023 SESPAS. Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Original Article
García-Sempere, Aníbal
Giménez, Estela
Vanaclocha, Hermelinda
Limón, Ramón
Peiró, Salvador
Navarro, David
Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title_full Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title_fullStr Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title_full_unstemmed Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title_short Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022
title_sort seroprevalence of antibodies against sars-cov-2 in the valencian community (spain) as of october 2022
topic Brief Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192597/
https://www.ncbi.nlm.nih.gov/pubmed/37331154
http://dx.doi.org/10.1016/j.gaceta.2023.102312
work_keys_str_mv AT garciasempereanibal seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022
AT gimenezestela seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022
AT vanaclochahermelinda seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022
AT limonramon seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022
AT peirosalvador seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022
AT navarrodavid seroprevalenceofantibodiesagainstsarscov2inthevalenciancommunityspainasofoctober2022

Ejemplares similares